شحن متتبَّع إلى جميع أنحاء العالم | خلال 9–14 يوم عمل تقريبًا

سلتك

سلة التسوق فارغة

ابدأ التصفح

شحن مجاني على الطلبات التي تزيد عن €500.

المجموع الفرعي€0
المتابعة إلى الدفع
الأيضدواء معتمد

Tesamorelin

البحوث المنشورة وقاعدة الأدلة

Tesamorelin (TH9507) is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates endogenous, pulsatile growth hormone secretion via the GHRH receptor. It was evaluated in large multicentre phase 3 trials in people with HIV and excess abdominal fat, where visceral adipose tissue was the primary endpoint, and was subsequently approved for HIV-associated lipodystrophy. Later investigator-initiated trials extended the work to hepatic fat in NAFLD/MASLD, to neurocognitive endpoints in mild cognitive impairment and in HIV, and to lean mass and physical function. Recent literature is dominated by meta-analyses of the HIV lipodystrophy trials, MASLD reviews, and preclinical GHRH-agonist neurobiology.

باختصار
  • تيساموريلين هو نظير اصطناعي للهرمون المطلق لهرمون النمو البشري.
  • أفادت دراسات على أشخاص مصابين بفيروس نقص المناعة البشرية بانخفاض الدهون الحشوية والكبدية.
  • تظل الأدلة خارج تراكم الدهون المرتبط بفيروس نقص المناعة البشرية محدودة وغير متسقة.

34 دراسة · 13 منذ 2023 · الأحدث 2026

الدراسات المذكورة
34
منشورة 2023+
13
أحدث ورقة بحثية
2026
آخر مراجعة
أكتوبر 2026

المواضيع المتكررة في الأدبيات

  • HIV-associated lipodystrophy and visceral adipose tissue reduction
  • Hepatic fat fraction, NAFLD/MASLD in people with HIV
  • GHRH receptor signalling and endogenous GH pulsatility
  • Cognition, brain connectivity and mild cognitive impairment
  • Lean body mass and physical function preservation
  • Safety signals: glucose homeostasis, arthralgia, IGF-1 elevation

معرّفات المركب

CAS
218949-48-5
PubChem
16137828

الهوية الكيميائية

ما هو Tesamorelin، كيميائياً.

الصيغة الجزيئية
C221H366N72O67S
الوزن الجزيئي
5136 g/mol
رقم CAS
218949-48-5
PubChem CID
16137828
يُكتب أيضاً كـ

TH 9507

هذه الأرقام مأخوذة من سجل PubChem لهذا المركب وتصف القاعدة الحرة. يتم توفير الببتيد المجفف بالتجميد عادةً كملح أسيتات أو ترايفلوروأسيتات ويحتوي على ماء متبقٍ، لذا فإن كتلة المسحوق في القارورة ليست نفس الكمية التي يشير إليها الوزن الجزيئي أعلاه. النقاء الكروماتوغرافي في شهادة التحليل لا يحل هذا الفرق أيضاً — كيفية قراءة شهادة التحليل يوضح السبب.

الأدلة

34 دراسة منشورة.

مرتبة حسب قوة تصميم الدراسة، ثم حسب الحداثة. كل إدخال يرتبط بالسجل المصدري حتى يمكن التحقق من النتيجة مقابل الورقة البحثية بدلاً من الاعتماد على كلامنا.

  1. 01مراجعة منهجية2026

    Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis

    Ditta AM, et al. · Journal of the International Association of Providers of AIDS Care · systematic review and meta-analysis of 4 randomised controlled trials, 909 participants with HIV-associated lipodystrophy

    Pooled analysis reported reductions in visceral adipose tissue and waist circumference and an increase in lean body mass with tesamorelin 2 mg relative to placebo. The authors also recorded higher discontinuation rates and growth hormone-related adverse effects in the treatment arms.

  2. 02مراجعة منهجية2026

    Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

    Badran AS, et al. · Obesity Research & Clinical Practice · meta-analysis of 5 randomised controlled trials in HIV-associated lipodystrophy

    Tesamorelin was associated with reductions in visceral adipose tissue (mean difference -27.71 cm2), trunk fat and hepatic fat, and with an increase in lean body mass (mean difference 1.42 kg). Reported adverse events included arthralgia, myalgia and paraesthesia.

  3. 03سريري بشري2026

    The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment

    Stewart CE, et al. · eNeurologicalSci · randomised placebo-controlled study, n=22 adults spanning normal cognition to mild cognitive impairment, 1 mg tesamorelin, 10 weeks

    Low-dose GHRH treatment was not directly associated with significant changes in the study's cognitive measures over 10 weeks. Machine-learning analysis of imaging data identified candidate differences in connectivity within cognition-related brain regions.

  4. 04سريري بشري2026

    Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol

    Erlandson KM, et al. · BMJ Open · randomised controlled trial protocol, planned n=100 sedentary adults aged 50-80 with HIV, 24 weeks treatment plus 24-week exercise extension (NCT06554717)

    The protocol described a trial testing tesamorelin combined with exercise, with endpoints covering physical function, muscle quality, quality of life and metabolic markers. No outcome data were reported, as the paper described study design only.

  5. 05سريري بشري2025

    Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity

    Ellis RJ, et al. · The Journal of Infectious Diseases · phase 2 multicentre randomised trial, n=73 persons with HIV and abdominal obesity, 6 months

    Within-group cognitive change in the tesamorelin arm approached but did not reach significance (P=.060), and the between-group difference versus standard care was not significant (P=.673). Greater reduction in waist circumference was observed in the tesamorelin arm.

  6. 06سريري بشري2025

    Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

    Mihalache A, et al. · Cureus · pharmacovigilance disproportionality analysis of FDA Adverse Event Reporting System reports, October 2003 to September 2024, covering all drugs with at least 10 primary-suspect carpal tunnel syndrome reports

    Tesamorelin was one of ten drugs with significant over-reporting of carpal tunnel syndrome (reporting odds ratio 20.7, 95% CI 13.7-31.3), alongside enzyme replacement therapies, aromatase inhibitors and bisphosphonates. The authors called for vigilance and monitoring for new or worsening carpal tunnel syndrome in people prescribed these drugs.

    نتيجة سلامة مُبلغ عنها. Disproportionate reporting of carpal tunnel syndrome with tesamorelin in FAERS (reporting odds ratio 20.7).

  7. 07سريري بشري2024

    Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

    Russo SC, et al. · AIDS · randomised placebo-controlled trial, 31 completers (15 tesamorelin, 16 placebo) with HIV on integrase strand transfer inhibitors, 12 months

    Tesamorelin was associated with declines in visceral fat, hepatic fat and the trunk-to-appendicular fat ratio relative to placebo in participants receiving integrase inhibitor regimens. Adverse event frequency was similar between groups.

  8. 08سريري بشري2021

    Tesamorelin improves fat quality independent of changes in fat quantity.

    Lake JE, et al. · AIDS · secondary analysis of two randomised placebo-controlled trials, people with HIV and central adiposity, 193 tesamorelin visceral-fat responders and 148 placebo recipients, CT, 26 weeks

    Visceral fat density rose by 6.2 HU with tesamorelin versus 0.3 HU with placebo, and subcutaneous fat density by 4.0 versus 0.3 HU (both P < 0.0001), and the effect persisted after adjustment for change in fat area. The authors interpreted higher density as better fat quality.

  9. 09سريري بشري2020

    Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

    Fourman LT, et al. · JCI Insight · analysis of paired liver biopsies from a randomised placebo-controlled trial of tesamorelin in people with HIV-associated NAFLD, 1 year

    Compared with placebo, tesamorelin increased hepatic expression of gene sets involved in oxidative phosphorylation and decreased gene sets for inflammation, tissue repair and cell division, and shifted gene sets linked to hepatocellular carcinoma prognosis in a favourable direction. Among tesamorelin recipients these changes correlated with an improved fibrosis-related gene score.

  10. 10سريري بشري2019

    Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    Stanley TL, et al. · The Lancet HIV · randomised, double-blind, placebo-controlled multicentre trial, n=61 people with HIV and NAFLD, 12 months

    Hepatic fat fraction fell more in the tesamorelin group than in the placebo group, with an absolute effect size of -4.1% (p=0.018). At 12 months, 35% of tesamorelin recipients versus 4% of placebo recipients had a hepatic fat fraction below 5%.

  11. 11سريري بشري2019

    The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

    Adrian S, et al. · J Frailty Aging · secondary exploratory analysis of two randomised phase 3 trials, people with HIV and abdominal obesity, 193 tesamorelin visceral-fat responders versus 148 placebo recipients, CT at L4-L5, 26 weeks

    Compared with placebo, tesamorelin responders had greater increases in the density of four truncal muscle groups (all p<0.005), indicating less muscle fat, and in lean muscle area of all four groups. The analysis was restricted to participants whose visceral fat fell by at least 8%.

  12. 12سريري بشري2017

    Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

    Clemmons DR, et al. · PLoS One · RCT, n=53, 12 weeks, type 2 diabetes

    Tesamorelin did not alter relative insulin response, fasting glucose, HbA1c or overall diabetes control versus placebo over 12 weeks. Total and non-HDL cholesterol decreased in the higher-dose group and no participant discontinued for loss of diabetes control.

    نتيجة سلامة مُبلغ عنها. Glycaemic control was not worsened in people with type 2 diabetes over 12 weeks.

  13. 13سريري بشري2017

    Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

    Fourman LT, et al. · AIDS · post hoc analysis of two phase 3 randomised trials (806 people with HIV and abdominal obesity), restricted to tesamorelin recipients with baseline ALT or AST above 30 U/l, 26 weeks plus 26-week follow-up

    Among tesamorelin recipients with raised baseline transaminases, visceral-fat responders had greater reductions in ALT (-8.9 vs +1.4 U/l, P = 0.004) and AST (-3.8 vs +0.4 U/l, P = 0.04) than non-responders over 26 weeks. The improvement persisted to 52 weeks even in those switched to placebo.

  14. 14سريري بشري2015

    Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

    González-Sales M, et al. · Clin Pharmacokinet · population pharmacokinetic analysis of phase 1 data, n=38 people with HIV and healthy participants given subcutaneous tesamorelin for 14 days

    An open one-compartment model described tesamorelin plasma concentrations, with an estimated clearance of 1,060 L/h and a volume of distribution of 200 L. Age, body size, race and HIV status were not related to tesamorelin pharmacokinetics.

  15. 15سريري بشري2014

    Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

    Stanley TL, et al. · JAMA · randomised placebo-controlled trial, n=48 (28 tesamorelin, 22 placebo) with HIV and abdominal fat accumulation, 6 months

    Visceral adipose tissue decreased by 34 cm2 with tesamorelin versus an increase of 8 cm2 with placebo (p=0.005). Liver fat, measured as lipid-to-water percentage, showed a net reduction of 2.9%.

  16. 16سريري بشري2014

    The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

    Makimura H, et al. · J Clin Endocrinol Metab · 31P magnetic resonance spectroscopy substudy of a 12-month randomised double-blind placebo-controlled trial, n=39 obese men and women with reduced GH secretion

    IGF-1 rose more with tesamorelin than with placebo (P=.02), and increases in IGF-1 correlated with faster phosphocreatine recovery after submaximal exercise (R=0.56, P=.01), more strongly among tesamorelin-treated participants (R=0.71). The authors interpreted this as suggestive of improved mitochondrial function.

  17. 17سريري بشري2013

    Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

    Friedman SD, et al. · JAMA Neurol · randomised double-blind placebo-controlled MR spectroscopy substudy of a larger trial, n=30 adults aged 55 to 87 (17 with mild cognitive impairment), 20 weeks

    After 20 weeks GABA levels rose in all three brain regions measured (P < .04), N-acetylaspartylglutamate rose in the dorsolateral frontal cortex and myo-inositol fell in the posterior cingulate, with similar effects in mild cognitive impairment and normal cognition; glutamate did not change. A favourable treatment effect on cognition was seen in the substudy (P = .03), but the neurochemical changes were not associated with the cognitive changes.

  18. 18سريري بشري2013

    Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers.

    Teng S, et al. · Clin Pharmacol Drug Dev · two randomised two-way crossover drug-interaction studies in healthy volunteers, tesamorelin with simvastatin or ritonavir

    Simvastatin exposure ratios with and without tesamorelin fell within the no-effect range of 80-125%. For ritonavir, exposure ratios were approximately 90% and the lower confidence limit for peak concentration was 74.8%, and the authors concluded that tesamorelin has minimal, if any, effect on CYP3A activity.

  19. 19سريري بشري2012

    Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

    Baker LD, et al. · Archives of Neurology · randomised double-blind placebo-controlled trial, 137 completers (66 with mild cognitive impairment), tesamorelin, 20 weeks

    Intent-to-treat analysis indicated a favourable effect of GHRH administration on a composite cognitive measure (P=.03), with the strongest signal in executive function (P=.005). Effects were observed in both the mild cognitive impairment and healthy older adult groups.

  20. 20سريري بشري2012

    Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

    Makimura H, et al. · J Clin Endocrinol Metab · RCT, n=60, 12 months, abdominal obesity with reduced GH secretion, without HIV

    Tesamorelin reduced visceral fat, carotid intima-media thickness, C-reactive protein and triglycerides versus placebo, without effect on subcutaneous fat or glucose measures. IGF-I rose and there were no serious adverse events.

  21. 21سريري بشري2012

    Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

    Stanley TL, et al. · Clin Infect Dis · post hoc responder analysis of two randomised double-blind phase 3 trials, 402 people with HIV-associated abdominal fat initially assigned to tesamorelin, 26 and 52 weeks

    Participants whose visceral fat fell by at least 8% had larger triglyceride reductions and better adiponectin levels than non-responders. Non-responders showed rises in fasting glucose and in HbA1c (0.3% at 26 weeks and 0.2% at 52 weeks), whereas glucose homeostasis was preserved in responders.

    نتيجة سلامة مُبلغ عنها. Fasting glucose and HbA1c rose in tesamorelin-treated participants whose visceral fat did not respond.

  22. 22سريري بشري2011

    Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

    Stanley TL, et al. · AIDS · secondary analysis of a randomised placebo-controlled phase 3 trial in people with HIV and abdominal adiposity (273 tesamorelin, 137 placebo), 26 weeks

    Tissue plasminogen activator antigen fell more with tesamorelin than with placebo (P < 0.05), while the change in PAI-1 antigen was not significant. Among tesamorelin recipients, changes in PAI-1, tPA and adiponectin were associated with the change in visceral fat.

  23. 23سريري بشري2011

    Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

    Stanley TL, et al. · J Clin Endocrinol Metab · single-arm interventional physiology study in thirteen healthy men, 2 weeks of treatment followed by 2 weeks of withdrawal

    Tesamorelin increased mean overnight GH (P = 0.004), GH peak area and basal GH secretion, and raised IGF-1 (P < 0.0001). Neither fasting glucose (P = 0.93) nor clamp-measured insulin-stimulated glucose uptake (P = 0.61) changed significantly.

  24. 24سريري بشري2010

    Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

    Falutz J, et al. · J Clin Endocrinol Metab · pooled analysis of two phase 3 RCTs, n=806, 26 weeks plus 26-week extension

    Tesamorelin reduced visceral adipose tissue (treatment effect -15.4% versus placebo) at 26 weeks without significant change in abdominal subcutaneous fat, and lowered triglycerides. Reductions were maintained to 52 weeks with continued treatment, and glucose parameters did not differ meaningfully between groups.

  25. 25سريري بشري2010

    Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

    Falutz J, et al. · J Acquir Immune Defic Syndr · randomised double-blind placebo-controlled phase 3 trial with a re-randomised extension, n=404 people with HIV and excess abdominal fat on antiretroviral therapy, 6 months plus 6-month extension

    Visceral adipose tissue fell by 10.9% with tesamorelin versus 0.6% with placebo over 6 months (P < 0.0001), with improvements in trunk fat, waist circumference and ratings of belly appearance distress, a rise in IGF-1 and no change in glucose parameters. Visceral fat was about 18% lower in those continuing tesamorelin for 12 months, and the gains were rapidly lost in those switched to placebo.

  26. 26سريري بشري2008

    Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

    Falutz J, et al. · AIDS · phase 3 RCT extension, n=410 randomised, 52 weeks, HIV with abdominal fat

    Adverse events in the extension phase were comparable with the initial phase and glucose parameters did not change in a clinically significant way over 52 weeks. Visceral fat reduction (-18%) and triglyceride reduction were sustained during treatment, and visceral fat reaccumulated after discontinuation.

    نتيجة سلامة مُبلغ عنها. No clinically significant glucose changes occurred over 52 weeks; visceral fat reaccumulated after stopping.

  27. 27سريري بشري2007

    Metabolic effects of a growth hormone-releasing factor in patients with HIV

    Falutz J, et al. · The New England Journal of Medicine · multicentre randomised placebo-controlled trial, n=412 patients with HIV and abdominal fat accumulation, 26 weeks

    Visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group (p<0.001). Triglycerides fell by 50 mg/dL with tesamorelin versus a rise of 9 mg/dL with placebo (p<0.001).

  28. 28سريري بشري2005

    A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

    Falutz J, et al. · AIDS · randomised double-blind placebo-controlled phase 2 dose-ranging trial, n=61 people with HIV and abdominal fat accumulation, 12 weeks

    IGF-1 rose in a dose-related way, and trunk fat changed by -9.2% at the higher dose versus 0.8% with placebo (P = 0.014) without significant change in limb fat. Visceral fat fell most at the higher dose (-15.7% versus -5.4% with placebo) but the difference was not significant; lean body mass improved, triglycerides fell at the higher dose and glucose did not change.

  29. 29حيواني داخل الجسم الحي2026

    Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models

    Pedrolli F, et al. · Cell Death & Disease · rat hippocampal neural stem cells and human neuroblastoma cells in vitro; 5xFAD transgenic mice treated with the GHRH agonist MR-409

    GHRH(1-44)NH2 promoted neural stem cell survival and differentiation under amyloid-beta exposure and engaged cAMP/PKA/CREB, ERK1/2 and PI3K/Akt signalling. In 5xFAD mice, MR-409 reduced amyloid-beta deposition, tau phosphorylation, gliosis and proinflammatory cytokine expression without altering systemic GH or IGF-1.

  30. 30مراجعة2026

    Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss

    Arora G, et al. · Journal of Clinical Medicine · narrative review of agents investigated for muscle preservation during weight loss

    The review placed tesamorelin among GHRH-directed agents examined for attenuating lean mass loss, alongside bimagrumab and enobosarm. It summarised the available trial evidence and noted that data specific to lean mass preservation during pharmacological weight loss remained limited.

  31. 31مراجعة2025

    Metabolic dysfunction-associated steatotic liver disease in people with HIV

    Gattu AK, et al. · Current Opinion in HIV and AIDS · narrative review of MASLD epidemiology, diagnosis and therapeutics in people with HIV

    The review summarised the higher burden of steatotic liver disease in people with HIV and the diagnostic approaches used. It described dedicated studies of GLP-1 receptor agonists and the GHRH analogue tesamorelin as the main HIV-specific therapeutic evidence to date.

  32. 32مراجعة2025

    Growth hormone-releasing hormone receptor (GHRH-R) and its signaling

    Halmos G, et al. · Reviews in Endocrine and Metabolic Disorders · mechanistic review of GHRH receptor structure, splice variants and downstream signalling

    The review described pituitary and extrapituitary GHRH receptor expression, splice variant biology and the cAMP-dependent signalling engaged by GHRH agonists. It outlined therapeutic contexts spanning oncology, endocrinology, obesity and diabetes.

  33. 33مراجعة2025

    GHRH in diabetes and metabolism

    Steenblock C, et al. · Reviews in Endocrine and Metabolic Disorders · review of GHRH and GHRH analogue effects on metabolic regulation and pancreatic islet biology

    The review reported that GHRH and its analogues enhanced survival of insulin-producing pancreatic beta cells in vitro and in animal models. It also summarised GHRH-axis involvement in adiposity and glucose metabolism.

  34. 34تقرير حالة2026

    Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.

    Beach R, et al. · Clin Infect Dis · two case reports, adults with well-controlled HIV and central adiposity, one treated with tesamorelin and one given tesamorelin after intermittent GLP-1 receptor agonist therapy

    In the first patient, with a BMI of 27 kg/m², tesamorelin was followed by marked reductions in waist circumference, improved lipid levels and better functional well-being. In the second, a woman with obesity whose access to a GLP-1 receptor agonist had been intermittent, tesamorelin was added to target visceral fat; the abstract gives no measured outcome for her.

القيود

ما لا تثبته هذه الأدلة.

Controlled evidence outside HIV-associated visceral adiposity and hepatic steatosis remains limited: cognitive trials have been small and inconsistent, the largest recent HIV neurocognitive trial found no significant between-group difference, and no histology-based endpoints in MASLD or long-term cardiovascular or oncological outcome data have been established. Effects on physical function and lean mass preservation in non-HIV populations are still under investigation, with the TRIUMPH protocol published but no results reported.

أسئلة شائعة حول البحث.

What is tesamorelin?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-44) with a stabilising hexenoyl modification at its N-terminus. It is studied in research on GHRH-receptor signalling, growth hormone pulsatility, and the IGF-1 axis.

How does tesamorelin differ from CJC-1295 and ipamorelin?

All three appear in growth-hormone-axis research, but through different mechanisms. Tesamorelin and CJC-1295 are GHRH analogues acting at the GHRH receptor, while ipamorelin is a ghrelin-mimetic acting at the GH secretagogue receptor (GHS-R1a). Tesamorelin is distinguished by its large clinical literature and its minimally modified full-length GHRH sequence.

What did the trials in HIV-associated lipodystrophy report?

The 2007 multicentre randomised placebo-controlled trial in 412 patients with HIV and abdominal fat accumulation reported a 15.2 percent decrease in visceral adipose tissue over 26 weeks against a 5.0 percent increase with placebo, and a fall in triglycerides of 50 mg/dL versus a rise of 9 mg/dL with placebo. A 2026 meta-analysis of five randomised controlled trials reported a pooled visceral adipose tissue mean difference of -27.71 cm2 and an increase in lean body mass of 1.42 kg. Reported adverse events across those trials included arthralgia and myalgia.

متاح من كتالوجنا

لأغراض البحث فقط. ليس للاستهلاك البشري أو التشخيص أو العلاج أو الوقاية من أي حالة. لا شيء في هذه الصفحة يعتبر نصيحة طبية، ولا ينبغي قراءة أي دراسة ملخصة هنا كتوصية.